Anti-bcma car t cell compositions
Assigneebluebird bio, Inc.
InventorsTravis QUIGLEY, Robert ROSS
Life of this patent
Estimating the term…
Abstract
The invention provides improved anti-BCMA CAR T cell compositions for adoptive T cell therapy for relapsed/refractory multiple myeloma.
Claims27
A composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells, wherein the therapeutically effective amount is at least about 15.0×107 anti-BCMA CAR T cells, and the anti-BCMA CAR comprises the amino acid sequence set forth in SEQ ID NO:
- 9.
(canceled)
(canceled)
-11. (canceled)
-14. (canceled)
(canceled)
A pharmaceutical composition comprising a population of T cells transduced with a lentivirus encoding an anti-BCMA CAR, wherein population of T cells comprises at least about 15.0×107 anti-BCMA CAR T cells, and the anti-BCMA CAR comprises the amino acid sequence set forth in SEQ ID NO:
- 9.
-20. (canceled)
-27. (canceled)
-30. (canceled)
(canceled)
Dependencies are inferred from the claim text.